As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

Your physical environment, social life and lifestyle have as much an influence on your biology − and hence, how you process drugs − as your genes.

Patient was on maximal therapy for asthma ... of biologic therapy options, including anti IgE, anti IL5, and anti IL4 receptor alpha, including different mechanisms of action, side effects ...

Your genes play a major role in determining your height, hair and eye color, and skin tone, but they don't tell the entire ...

Figuring out how your genes and environment increase your likelihood of developing asthma ... these differences in drug effects between patients? Is it their genes? Are they not taking their ...

Bullous pemphigoid (BP), which has no FDA-approved targeted therapies, leads to reddening of the skin and the formation of ...

Your genes play a major role in determining your height, hair and eye color and skin tone, but they don’t tell the entire ...

An estimated 5,000 people in the United States are living with Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare ...

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).

As I've grown older and experienced the vagaries of my ageing memory, I've often reflected on the possibility of a miracle ...